Arcutis Biotherapeutics Valuation
| ARQT Stock | USD 10.14 0.10 0.98% |
At this time, the firm appears to be undervalued. Arcutis Biotherapeutics shows a prevailing Real Value of $16.34 per share. The current price of the firm is $10.14. Our model approximates the value of Arcutis Biotherapeutics from analyzing the firm fundamentals such as profit margin of (1.41) %, and Return On Equity of -1.92 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Arcutis Biotherapeutics' valuation include:
Price Book 7.6515 | Enterprise Value 1.1 B | Enterprise Value Ebitda (2.04) | Price Sales 8.6407 | Enterprise Value Revenue 7.7584 |
Undervalued
Today
Please note that Arcutis Biotherapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Arcutis Biotherapeutics is based on 3 months time horizon. Increasing Arcutis Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Arcutis Biotherapeutics' intrinsic value may or may not be the same as its current market price of 10.14, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.14 | Real 16.34 | Target 36.63 | Hype 10.24 | Naive 9.91 |
The intrinsic value of Arcutis Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arcutis Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arcutis Biotherapeutics helps investors to forecast how Arcutis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcutis Biotherapeutics more accurately as focusing exclusively on Arcutis Biotherapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Arcutis Biotherapeutics' intrinsic value based on its ongoing forecasts of Arcutis Biotherapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Arcutis Biotherapeutics' closest peers.
Arcutis Biotherapeutics Cash |
|
Arcutis Valuation Trend
Arcutis Biotherapeutics' real value is important for investors to make better decisions and a more accurate overall view of Arcutis Biotherapeutics' financial worth over time. Using both Arcutis Biotherapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Arcutis Revenue by Product
Arcutis Biotherapeutics Total Value Analysis
Arcutis Biotherapeutics is presently projected to have valuation of 1.08 B with market capitalization of 1.2 B, debt of 205.92 M, and cash on hands of 282.17 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arcutis Biotherapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.08 B | 1.2 B | 205.92 M | 282.17 M |
Arcutis Biotherapeutics Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.67. Arcutis Biotherapeutics had not issued any dividends in recent years. Based on the key indicators related to Arcutis Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Arcutis Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Arcutis Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcutis Biotherapeutics has an asset utilization ratio of 17.46 percent. This implies that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Arcutis Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Arcutis Biotherapeutics Ownership Allocation
Arcutis Biotherapeutics holds a total of 117.05 Million outstanding shares. The majority of Arcutis Biotherapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcutis Biotherapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcutis Biotherapeutics. Please pay attention to any change in the institutional holdings of Arcutis Biotherapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arcutis Biotherapeutics Profitability Analysis
The company reported the previous year's revenue of 59.61 M. Net Loss for the year was (262.14 M) with profit before overhead, payroll, taxes, and interest of 2.93 M.About Arcutis Biotherapeutics Valuation
The stock valuation mechanism determines Arcutis Biotherapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Arcutis Biotherapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Arcutis Biotherapeutics. We calculate exposure to Arcutis Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arcutis Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 54.6 M | 57.3 M | |
| Pretax Profit Margin | (4.35) | (4.56) | |
| Operating Profit Margin | (4.04) | (4.25) | |
| Net Loss | (4.40) | (4.62) | |
| Gross Profit Margin | 0.92 | 0.69 |
Arcutis Biotherapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Arcutis Biotherapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 69.3 M |
Arcutis Biotherapeutics Current Valuation Indicators
Arcutis Biotherapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Arcutis Biotherapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Arcutis Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Arcutis Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Arcutis Biotherapeutics' worth.Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.